Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance


Butt G., Shahwar D., Qureshi M. Z. , Attar R., Akram M., Birinci Y., ...Daha Fazla

BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, cilt.1152, ss.283-292, 2019 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 1152
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/978-3-030-20301-6_15
  • Dergi Adı: BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION
  • Sayfa Sayıları: ss.283-292

Özet

Based on the insights gleaned from decades of research, it seems clear that mechanistic target of rapamycin (mTOR) is an essential signaling node that integrates environmental clues for regulation of cell survival, metabolism and proliferation of the cells. However, overwhelmingly increasing scientific evidence has added a new layer of intricacy to already complicated and versatile signaling pathway of mTOR. Deregulation of spatio-temporally controlled mTOR-driven pathway played contributory role in breast cancer development and progression. Pharmacologists and molecular biologists have specifically emphasized on the identification and development of mTOR-pathway inhibitors. In this chapter we have attempted to provide an overview of the most recent findings related to therapeutic targeting of mTOR-associated mTORC1 and mTORC2 in breast cancer. We have also comprehensively summarized regulation of mTOR and its partners by microRNAs in breast cancer.